GlassScriptPhysician profile
Chukwuemeka Obidi
NPI 1083796452
$2,443.19
in general payments reported to CMS, 2019-2025
28 companies · $287 in 2025
The $287 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $188 · 2021: $482 · 2022: $303 · 2023: $132 · 2024: $573 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $627.38 | 2019-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $227.95 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Kaleo, INC. | $205.23 | 2019-2022 | |
| Cranial Technologies, INC | $191.29 | 2019-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $187.49 | 2019-2022 | |
| Neos Therapeutics, LP | $124.57 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $95.78 | 2019-2023 | Jornay Pm |
| Abbvie INC. | $91.33 | 2021-2022 | |
| Genentech USA, INC. | $75.71 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $65.18 | 2019-2024 | Relexxii |
| Adlon Therapeutics L.P. | $64.86 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $52.49 | 2021-2025 | Koselugo |
| Shire North American Group INC | $44.97 | 2019 | |
| Pfizer INC. | $43.28 | 2019-2020 | |
| Tris Pharma INC | $42.19 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $41.75 | 2021-2023 | |
| Glaxosmithkline, LLC. | $39.28 | 2021-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $31.80 | 2021-2024 | Rybelsus, Ozempic |
| Ironwood Pharmaceuticals, INC | $24.24 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $21.29 | 2024 | Crysvita |
| Seqirus USA INC | $20.89 | 2025 | Flucelvax, Fluad |
| Kyowa Kirin, INC. | $20.63 | 2025 | |
| Hologic Sales and Service, LLC | $19.98 | 2025 | Aptima |
| Medtronic, INC. | $18.29 | 2025 | Inceptiv |
| Amag Pharmaceuticals, INC. | $18.05 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.53 | 2025 | Zoryve |
| Lilly USA, LLC | $16.18 | 2020 | |
| Collegium Pharmaceutical, INC. | $13.58 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chukwuemeka Obidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.